Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tas-102 and Y90 Radioembolization in Refractory mCRC
NCT02602327Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Jan 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil in colorectal cancer (CRC), sponsored by University of California, San Francisco. Primary endpoints: Dose Limiting Toxicities at 56 days and Maximum Tolerated Dose at 4 years. Started Jan 2017; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02602327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02602327.